The United States Food & Drug Administration recently approved a competitor to Botox®. Marketed in the United State by Medicis corporation, Dysport™ is a form of botulinum toxin A, abobotulinumtoxinA. The product has been used in Europe for some time but just last week received clearance from the US FDA for marketing in the United States. Initial clinical trials were performed under the name Reloxin™ but final approval was given for marketing under the name Dysport™. At the time of this writing, final information from Medicis as to price and availability of Dysport™ for use in cosmetic procedures is unavailable. Dysport™is indicated for the temporary improvement int he appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients < 65 years of age.